About Echo Biotech

Beijing Echo Biotech Co., Ltd. is a biotechnology company focused on the development, scalable manufacturing and clinical translation of extracellular vesicle technologies, particularly exosomes.

Quick Facts

  • Beijing Echo Biotech Co., Ltd. is a biotechnology company focused on the development, scalable manufacturing and clinical translation of extracellular vesicle technologies, partic…
  • Company Profile: Beijing Echo Biotech Co., Ltd.
  • Core Technology Platforms: Addressing the critical steps from scientific discovery to product translation, the company has established three core technology platforms: Exoomics®,…
  • Research and Collaboration: To date, Echo Biotech has established collaborations with more than 2,000 hospitals, universities, research institutions, and industry partners in Chin…
  • Qualifications and Growth: The company has been recognized as a Beijing Specialized, Refined, Distinctive, and Innovative SME and a National High-Tech Enterprise, operates a postd…
  • Engineered Exosomes and International Filings: In engineered exosomes, research from the company's proprietary foundational technology platform was published in the Journal of Ext…
  • National Key R&D Program: At the end of 2024, Echo Biotech joined a project under China's National Key R&D Program, "Stem Cell Research and Organ Repair," contributing to the deve…
  • Mission: Echo Biotech is committed to advancing exosomes from research tools to standardized products and innovative therapies through scalable, evaluable, reproducible, and trans…
  • Brand Vision: Better Life with Exosomes.

Page Overview

Beijing Echo Biotech Co., Ltd. is a biotechnology company focused on the development, scalable manufacturing and clinical translation of extracellular vesicle technologies, particularly exosomes.

Page Items

Company Profile: Beijing Echo Biotech Co., Ltd. (Echo Biotech) is a biotechnology company focused on the development, scalable manufacturing, and clinical translation of extracellular vesicle (EV) technologies, particularly exosomes.

Core Technology Platforms: Addressing the critical steps from scientific discovery to product translation, the company has established three core technology platforms: Exoomics®, its exosome multi-omics and research services platform; Echosome®, its engineered exosome technology platform; and EchoPharm®, its large-scale exosome manufacturing and CMC platform. Together, they form an integrated technology system spanning exosome isolation and characterization, multi-omics analysis, engineering, process development, quality evaluation, large-scale manufacturing, and clinical translation.

Research and Collaboration: To date, Echo Biotech has established collaborations with more than 2,000 hospitals, universities, research institutions, and industry partners in China and worldwide. The company has supported the publication of more than 300 exosome-related papers, with research covering over 100 sample types and more than 80,000 samples processed. These long-term, multi-source, and multi-scenario collaborations have enabled Echo Biotech to continuously build expertise and data in exosome biology, process development, quality control, and translational applications.

Qualifications and Growth: The company has been recognized as a Beijing Specialized, Refined, Distinctive, and Innovative SME and a National High-Tech Enterprise, operates a postdoctoral research workstation, and has completed multiple financing rounds totaling several hundred million RMB.

Engineered Exosomes and International Filings: In engineered exosomes, research from the company's proprietary foundational technology platform was published in the Journal of Extracellular Vesicles, a leading international journal in the EV field. GoldenExo®, the company's human mesenchymal stem cell-derived exosome raw material, has completed a U.S. FDA Type II Drug Master File (DMF) filing and an International Nomenclature Cosmetic Ingredient (INCI) registration, supporting its quality system development and international applications.

National Key R&D Program: At the end of 2024, Echo Biotech joined a project under China's National Key R&D Program, "Stem Cell Research and Organ Repair," contributing to the development of extracellular vesicle quality standards, evaluation methods, and reference material systems, and helping accelerate the standardization and industrialization of exosome technologies.

Mission: Echo Biotech is committed to advancing exosomes from research tools to standardized products and innovative therapies through scalable, evaluable, reproducible, and translatable technology systems, delivering safer, more effective, and more accessible solutions for regenerative medicine, disease treatment, and healthy longevity.

Brand Vision: Better Life with Exosomes.